Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis.
Mechanisms of oligodendrocyte regeneration from ventricular-subventricular zone-derived progenitor cells in white matter diseases.
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.
Vibsanin B Preferentially Targets HSP90β, Inhibits Interstitial Leukocyte Migration, and Ameliorates Experimental Autoimmune Encephalomyelitis.
Neurofilaments and NFL-TBS.40-63 peptide penetrate oligodendrocytes through clathrin-dependent endocytosis to promote their growth and survival in vitro.
MCAM(+) CD8 T lymphocytes mediate CNS inflammation.
Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis.
Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study.
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease.
Fingolimod Reduces Direct Medical Costs Compared to Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis in the Netherlands.
Chromatic visual evoked potentials in young patients with demyelinating disease.
Macrophages: A double-edged sword in experimental autoimmune encephalomyelitis.
Multiple Sclerosis: Improved Identification of Disease-relevant Changes in Gray and White Matter Using Susceptibility-based MR Imaging.
Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort.
The squares test as a measure of hand function in multiple sclerosis.
Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study.
Neuropsychological features in childhood and juvenile multiple sclerosis: Five-year follow-up.
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
Managing Disability in Progressive Multiple Sclerosis.
Alemtuzumab for multiple sclerosis.
[LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants].
Glia Maturation Factor Induces Interleukin-33 Release from Astrocytes: Implications for Neurodegenerative Diseases.
Multiple sclerosis or multiple possibilities: The continuing problem of misdiagnosis.
Monoclonal Antibodies in Treatment of Multiple Sclerosis.
Fatigue and sleep-disordered breathing in multiple sclerosis: a clinically relevant association?

Pages